MicroRNAs as theranostic markers in cardiac allograft
transplantation: from murine models to clinical practice

J 2021

MicroRNAs as theranostic markers in cardiac allograft transplantation: from murine models to clinical practice

NOVÁK, Jan, Táňa MACHÁČKOVÁ, Jan KREJČÍ, Julie DOBROVOLNÁ, Ondřej SLABÝ et. al.

Basic information

Original name

MicroRNAs as theranostic markers in cardiac allograft transplantation: from murine models to clinical practice

Authors

NOVÁK, Jan (203 Czech Republic, belonging to the institution), Táňa MACHÁČKOVÁ (203 Czech Republic, belonging to the institution), Jan KREJČÍ (203 Czech Republic, belonging to the institution), Julie DOBROVOLNÁ (203 Czech Republic, guarantor, belonging to the institution) and Ondřej SLABÝ (203 Czech Republic, belonging to the institution)

Edition

Theranostics, Lake Haven, Ivyspring International Publisher, 2021, 1838-7640

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

Australia

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 11.600

RIV identification code

RIV/00216224:14110/21:00120135

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.7150/thno.56327

UT WoS

000642591000004

Keywords in English

microRNA; biomarker; cardiac allograft transplantation; acute cellular rejection; vasculopathy

Abstract

V originále

Congestive heart failure affects about 23 million people worldwide, and cardiac allograft transplantation remains one of the last options for patients with terminal refractory heart failure. Besides the infectious or oncological complications, the prognosis of patients after heart transplantation is affected by acute cellular or antibody-mediated rejection and allograft vasculopathy development. Current monitoring of both conditions requires the performance of invasive procedures (endomyocardial biopsy sampling and coronary angiography or optical coherence tomography, respectively) that are costly, time-demanding, and non-comfortable for the patient. Within this narrative review, we focus on the potential pathophysiological and clinical roles of microRNAs (miRNAs, miRs) in the field of cardiac allograft transplantation. Firstly, we provide a general introduction about the status of cardiac allograft function monitoring and the discovery of miRNAs as post-transcriptional regulators of gene expression and clinically relevant biomarkers found in the extracellular fluid. After this general introduction, information from animal and human studies are summarized to underline the importance of miRNAs both in the pathophysiology of the rejection process, the possibility of its modulation by altering miRNAs levels, and last but not least, about the use of miRNAs in the clinical practice to diagnose or predict the rejection occurrence.

Links

EF15_003/0000469, research and development project

Name: Cetocoen Plus

EF17_043/0009632, research and development project

Name: CETOCOEN Excellence

MUNI/A/1403/2019, interní kód MU

Name: Diferenciální diagnostika a odhad prognózy interních nemocí 4 (Acronym: DIDIPRON 4)

Investor: Masaryk University, Category A

NV16-30537A, research and development project

Name: Cirkulující mikroRNA jako neinvazivní markery rejekce štěpu u pacientů po srdeční transplantaci

Files attached

1788739.pdf

Find similar documents

Citovat

NOVÁK, Jan, Táňa MACHÁČKOVÁ, Jan KREJČÍ, Julie DOBROVOLNÁ and Ondřej SLABÝ. MicroRNAs as theranostic markers in cardiac allograft transplantation: from murine models to clinical practice. Theranostics. Lake Haven: Ivyspring International Publisher, 2021, vol. 11, No 12, p. 6058-6073. ISSN 1838-7640. Available from: https://dx.doi.org/10.7150/thno.56327.

@article{1788739,
   author = {Novák, Jan and Macháčková, Táňa and Krejčí, Jan and Dobrovolná, Julie and Slabý, Ondřej},
   article_location = {Lake Haven},
   article_number = {12},
   doi = {http://dx.doi.org/10.7150/thno.56327},
   keywords = {microRNA; biomarker; cardiac allograft transplantation; acute cellular rejection; vasculopathy},
   language = {eng},
   issn = {1838-7640},
   journal = {Theranostics},
   title = {MicroRNAs as theranostic markers in cardiac allograft transplantation: from murine models to clinical practice},
   url = {https://www.thno.org/v11p6058.htm},
   volume = {11},
   year = {2021}
}

TY  - JOUR
ID  - 1788739
AU  - Novák, Jan - Macháčková, Táňa - Krejčí, Jan - Dobrovolná, Julie - Slabý, Ondřej
PY  - 2021
TI  - MicroRNAs as theranostic markers in cardiac allograft transplantation: from murine models to clinical practice
JF  - Theranostics
VL  - 11
IS  - 12
SP  - 6058-6073
EP  - 6058-6073
PB  - Ivyspring International Publisher
SN  - 18387640
KW  - microRNA
KW  - biomarker
KW  - cardiac allograft transplantation
KW  - acute cellular rejection
KW  - vasculopathy
UR  - https://www.thno.org/v11p6058.htm
N2  - Congestive heart failure affects about 23 million people worldwide, and cardiac allograft transplantation remains one of the last options for patients with terminal refractory heart failure. Besides the infectious or oncological complications, the prognosis of patients after heart transplantation is affected by acute cellular or antibody-mediated rejection and allograft vasculopathy development. Current monitoring of both conditions requires the performance of invasive procedures (endomyocardial biopsy sampling and coronary angiography or optical coherence tomography, respectively) that are costly, time-demanding, and non-comfortable for the patient. Within this narrative review, we focus on the potential pathophysiological and clinical roles of microRNAs (miRNAs, miRs) in the field of cardiac allograft transplantation. Firstly, we provide a general introduction about the status of cardiac allograft function monitoring and the discovery of miRNAs as post-transcriptional regulators of gene expression and clinically relevant biomarkers found in the extracellular fluid. After this general introduction, information from animal and human studies are summarized to underline the importance of miRNAs both in the pathophysiology of the rejection process, the possibility of its modulation by altering miRNAs levels, and last but not least, about the use of miRNAs in the clinical practice to diagnose or predict the rejection occurrence.
ER  -

NOVÁK, Jan, Táňa MACHÁČKOVÁ, Jan KREJČÍ, Julie DOBROVOLNÁ and Ondřej SLABÝ. MicroRNAs as theranostic markers in cardiac allograft transplantation: from murine models to clinical practice. \textit{Theranostics}. Lake Haven: Ivyspring International Publisher, 2021, vol.~11, No~12, p.~6058-6073. ISSN~1838-7640. Available from: https://dx.doi.org/10.7150/thno.56327.

Detailed Information on Publication Record